🏛️ Verified NIH Protocol • Sourced via U.S. National Library of Medicine (Last Synced: 2025-08-17)

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

🟢 Recruiting Phase 1 💊 Investigational Drug / Biologic Sponsor: Qurient Co., Ltd.

🩺 Protocol Summary

Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab

Primary Research Facility: Mayo Clinic (Phoenix, Arizona)

📋 Basic Study Criteria & Logistics Checklist

0 of 3 Checked

Review these 3 basic logistical and protocol criteria extracted from the public NIH record. (This is a preliminary logistical checklist, not an official clinical eligibility determination).

Diagnosed with, undergoing evaluation for, or seeking treatment related to Advanced Cancer?

🔍 Study Population / Focus Area (Source: Protocol Primary Condition)

Aged 18 Years or older?

🔍 Protocol Specified Minimum Age: 18 Years

Able to attend required in-person clinic visits and study procedures at one of the participating study centers?

🔍 Logistical Requirement: 11 Registered Participating Sites

📍 Primary Site Map

Site: Mayo Clinic — Phoenix, Arizona

📍 All Participating Trial Locations (11 Sites)

Multi-Center Trial

This protocol is enrolling participants across multiple clinical centers:

1. Mayo Clinic — Phoenix, Arizona

2. University of Southern California — Los Angeles, California

3. Mayo Clinic — Jacksonville, Florida

4. Northwestern University — Chicago, Illinois

5. Mayo Clinic — Rochester, Minnesota

6. Atlantic Health System Hospital — Morristown, New Jersey

7. Mary Crowley Cancer Research — Dallas, Texas

8. National Cancer Center — United States

9. CHA University Bundang Medical Center — United States

10. Asan Medical Center — United States

11. Severance Hospital — United States

📄 Print Doctor Discussion Sheet

Preview and print a 1-page summary with 5 tailored questions for your physician.

💰 Clinical Trial Costs & Insurance Coverage

Coverage for clinical trial participation varies depending on your health insurance policy, state legislation, and whether specific procedures are investigational research or routine medical care. Under federal law (Affordable Care Act § 2709), health insurers generally cannot drop coverage or refuse to pay for routine patient care costs incurred in approved clinical trials.

💡 Always ask the study coordinator for the trial's official Informed Consent Form, which outlines all sponsor-funded research items versus procedures billed to your insurance.

🏛️ Official Government Provenance

NIH ClinicalTrials.gov Protocol Record

NCT Identifier: NCT05394103 • Last Synced: 2025-08-17

View on ClinicalTrials.gov ↗